» Articles » PMID: 7239117

Cimetidine Impairs the Elimination of Theophylline and Antipyrine

Overview
Specialty Gastroenterology
Date 1981 Jul 1
PMID 7239117
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

In 7 healthy subjects theophylline and antipyrine elimination were determined before and during a course of oral cimetidine in a dose of 1 g/day. Plasma clearance of theophylline was reduced from 71.2 +/- 10.1 ml/min to 56.0 +/- 18.5 ml/min and the plasma clearance of antipyrine from 53.7 +/- 14.2 ml/min to 48.1 +/- 11.7 ml/min. Elimination half-life of theophylline was prolonged from 5.1 +/- 1.6 to 8.1 +/- 1.4 h. All these changes were statistically significant. Volume of distribution of theophylline (31.7 +/- 8.4 L before and 39.2 +/- 5.6 L during cimetidine administration) and plasma binding of theophylline (44.7 +/- 3.8% before and 44.3 +/- 3.1% during cimetidine administration) were not significantly different. Similarly, volume of distribution of antipyrine (45.8 +/- 14.0 vs. 47.6 +/- 17.9) was not significantly affected by cimetidine administration. We conclude that cimetidine impairs the elimination of theophylline and antipyrine in healthy subjects.

Citing Articles

Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions.

Sodhi J, Huang C, Benet L Clin Pharmacokinet. 2020; 60(2):205-222.

PMID: 32725383 PMC: 7385331. DOI: 10.1007/s40262-020-00926-7.


Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Klotz U, Reimann I Pharm Res. 2013; 1(2):59-62.

PMID: 24277213 DOI: 10.1023/A:1016347229923.


Differential pharmacokinetics of theophylline in elderly patients.

Ohnishi A, Kato M, Kojima J, Ushiama H, Yoneko M, Kawai H Drugs Aging. 2003; 20(1):71-84.

PMID: 12513116 DOI: 10.2165/00002512-200320010-00005.


Scaling basic toxicokinetic parameters from rat to man.

Bachmann K, Pardoe D, White D Environ Health Perspect. 1996; 104(4):400-7.

PMID: 8732950 PMC: 1469326. DOI: 10.1289/ehp.96104400.


The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders.

Milligan P, McGill P, Howden C, Kelman A, Whiting B Eur J Clin Pharmacol. 1993; 45(6):507-12.

PMID: 7908879 DOI: 10.1007/BF00315306.